[go: up one dir, main page]

BR0317567A - Composição farmacêutica de liberação controlada de tamsulosina e processo para sua preparação - Google Patents

Composição farmacêutica de liberação controlada de tamsulosina e processo para sua preparação

Info

Publication number
BR0317567A
BR0317567A BR0317567-7A BR0317567A BR0317567A BR 0317567 A BR0317567 A BR 0317567A BR 0317567 A BR0317567 A BR 0317567A BR 0317567 A BR0317567 A BR 0317567A
Authority
BR
Brazil
Prior art keywords
tamsulosin
pharmaceutical composition
controlled release
preparation
release pharmaceutical
Prior art date
Application number
BR0317567-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Girish Kumar Jain
Seetharaman Sritharan
Ashok Rampal
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of BR0317567A publication Critical patent/BR0317567A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0317567-7A 2002-12-20 2003-12-18 Composição farmacêutica de liberação controlada de tamsulosina e processo para sua preparação BR0317567A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1292DE2002 IN192381B (fr) 2002-12-20 2002-12-20
PCT/IB2003/006072 WO2004056354A1 (fr) 2002-12-20 2003-12-18 Compositions pharmaceutiques de tamsulosine a liberation controlee

Publications (1)

Publication Number Publication Date
BR0317567A true BR0317567A (pt) 2005-11-22

Family

ID=32676755

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317567-7A BR0317567A (pt) 2002-12-20 2003-12-18 Composição farmacêutica de liberação controlada de tamsulosina e processo para sua preparação

Country Status (9)

Country Link
EP (1) EP1596849A1 (fr)
JP (1) JP2006512358A (fr)
CN (1) CN1744889A (fr)
AU (1) AU2003288604A1 (fr)
BR (1) BR0317567A (fr)
CA (1) CA2511208A1 (fr)
IN (1) IN192381B (fr)
RU (1) RU2005121999A (fr)
WO (1) WO2004056354A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2515585A1 (fr) * 2003-01-27 2004-08-12 Yoji Tanijiri Particules fines keratinisees pour la liberation prolongee de tamsulosine ou de son sel, et leur procede de production
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
DK1618873T3 (da) * 2004-07-14 2007-10-08 Siegfried Generics Int Ag Granulat til kontrolleret frigivelse af tamsulosin, indeholdende alginat
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN101453996B (zh) * 2006-04-03 2016-05-11 伊萨·奥迪迪 药物递送组合物
CN104825397A (zh) 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2008089593A1 (fr) * 2007-01-18 2008-07-31 Standard Chem. & Pharm. Co., Ltd. Preparation de tamsulosine a liberation prolongee et procede de production associe
EP2308483A4 (fr) * 2008-07-01 2014-09-10 Sawai Seiyaku Kk Procédé de production de microparticules sphériques comprenant du chlorhydrate de tamsulosine
CN101695478B (zh) * 2009-10-23 2012-01-18 江苏大学 盐酸坦索罗辛缓释微丸制剂及其制备方法
KR101423237B1 (ko) 2010-05-04 2014-07-30 주식회사 삼양바이오팜 탐스로신 또는 이의 약학적으로 허용 가능한 염을 포함하는 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
CN103315962A (zh) * 2013-02-01 2013-09-25 北京科信必成医药科技发展有限公司 一种坦索罗辛缓释微丸制剂及其制备方法
CN103142492A (zh) * 2013-02-01 2013-06-12 北京科信必成医药科技发展有限公司 一种缓释微丸制剂及其制备方法
CN103919735B (zh) * 2014-05-04 2018-04-17 翰宇药业（武汉）有限公司 一种盐酸坦索罗辛缓释微丸及其制备方法
EP2949319A1 (fr) 2014-05-26 2015-12-02 Galenicum Health S.L. Compositions pharmaceutiques comprenant un agent actif
KR20190019061A (ko) * 2016-05-04 2019-02-26 아스펜 파크 파마슈티컬스 인코포레이티드 지연된 방출 경구 탐술로신 하이드로클로라이드
EP3473244A1 (fr) 2017-10-20 2019-04-24 Veru Inc. Chlorhydrate de tamsulosine à libération contrôlée destiné à être administré par voie orale
EP3473245A1 (fr) 2017-10-20 2019-04-24 Veru Inc. Chlorhydrate de tamsulosine à libération contrôlée destiné à être administré par voie orale
KR20200078146A (ko) * 2018-12-21 2020-07-01 한미약품 주식회사 내산성이 우수한 탐수로신 염산염 함유 제약 조성물 및 이의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1064938A1 (fr) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Formes pharmaceutiques à libération contrôlée avec au moins une impulsion temporelle
HUP0401978A3 (en) * 2001-11-07 2008-07-28 Synthon Bv Tamsulosin tablets

Also Published As

Publication number Publication date
IN192381B (fr) 2004-04-10
EP1596849A1 (fr) 2005-11-23
AU2003288604A1 (en) 2004-07-14
RU2005121999A (ru) 2006-01-20
CA2511208A1 (fr) 2004-07-08
CN1744889A (zh) 2006-03-08
JP2006512358A (ja) 2006-04-13
WO2004056354A1 (fr) 2004-07-08

Similar Documents

Publication Publication Date Title
BR0317567A (pt) Composição farmacêutica de liberação controlada de tamsulosina e processo para sua preparação
BRPI0110914B8 (pt) 'composição farmacêutica líquida, processo para preparação da mesma e uso de uma composicão farmacêutica'
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
MXPA04003742A (es) Farmaco conteniendo 3-(3-dimetilamino-1-etil-2-metil-propil)fenol con liberacion lenta de la sustancia activa.
BRPI0212455B8 (pt) composto derivado de fenetanolamina para o tratamento de doenças respiratórias, formulação farmacêutica, combinação, e, uso do mesmo
BR0315720A (pt) Composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìmefero, formulação farmacêutica, combinação, uso de um composto, processo para a preparação de um composto, e, intermediário
BRPI0518266A2 (pt) medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular
CA2447924A1 (fr) Formulations d'olopatadine a administration topique
BR0113626A (pt) Formulações de liberação sustentada para secretores de hormÈnio do crescimento
BRPI0410477A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto
BR0011116A (pt) Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
BRPI0412241A (pt) formulação para medicamentos de proteìna sem adição de albumina de soro humano (hsa)
PA8559401A1 (es) Sales de acido succinico de 5,7,14-triazatetraciclo (10.3.1.0 2,11.0 4, 9)-hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas.
BRPI0408990A (pt) derivados de pirimidin-4-ona e sua utilização como moduladores da p38-cinase
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
JP4832045B2 (ja) メキタジン、イブプロフェン及びトラネキサム酸含有医薬組成物
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
BRPI0316908B8 (pt) preparo de suspensões aquosas estéreis incluindo ingredientes ativos cristalinos micronizados para inalação
NO20013060D0 (no) Kontrollert frigjörende farmasöytisk preparat med tilidinmesylat som virkestoff
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
NO20070952L (no) Formuleringer av suberoylanilidhydroksaminsyre og fremgangsmate for fremstilling av slike
IL148874A0 (en) Sulfonyl amino acid derivatives, their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired